Filter news by date News Tags - Any -News storyPress release Month MonthJanuaryFebruaryMarchAprilMayJuneJulyAugustSeptemberOctoberNovemberDecember Year Year20252024202320222021202020192018201720162015201420132012201120102009200820072006 Apply 10 . 21 . 2024 Press release ASDS 2024: new phase III READY-4 data demonstrate long-term safety and efficacy of Galderma’s RelabotulinumtoxinA (Relfydess™) 10 . 17 . 2024 News story ASDS 2024: Galderma presents data on RelabotulinumtoxinA and Sculptra® 9 . 25 . 2024 Press release EADV 2024 Late breaking news sessions: new Galderma data demonstrating nemolizumab’s long-term efficacy and safety in atopic dermatitis and durability in prurigo nodularis to be shared during three oral presentations 9 . 17 . 2024 News story EADV 2024: scientific presentations supported by Galderma 9 . 17 . 2024 Press release Galderma reaffirms its leadership in dermatology with extensive presence at EADV 2024 9 . 13 . 2024 News story Identifying unmet patient needs on World Atopic Eczema Day 9 . 4 . 2024 Press release Galderma launches Cetaphil Gentle Exfoliating line with Gen-Z it-girl Katie Fang 8 . 29 . 2024 Press release Galderma successfully issued an inaugural CHF 500 million bond 8 . 13 . 2024 Press release Galderma receives U.S. FDA approval for Nemluvio® (nemolizumab) for adult patients living with prurigo nodularis 8 . 5 . 2024 Press release Galderma to pursue a new scientific partnership with L’Oréal to further advance its category leadership in dermatology 7 . 30 . 2024 Press release Galderma’s Relfydess™ (RelabotulinumtoxinA) receives positive decision for use in Europe 7 . 25 . 2024 Press release Phase III Arcadia 1 and 2 trial primary results published in The Lancet: Galderma’s nemolizumab improves key aspects of atopic dermatitis – itch, skin lesions and sleep disturbance Pagination Previous page Previous Page Next page Next Page